IN2014MN01936A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01936A IN2014MN01936A IN1936MUN2014A IN2014MN01936A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A IN 1936MUN2014 A IN1936MUN2014 A IN 1936MUN2014A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A
- Authority
- IN
- India
- Prior art keywords
- cancer
- level
- getting
- risk
- female subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 201000011510 cancer Diseases 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 2
- 108010054321 proneurotensin Proteins 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608346P | 2012-03-08 | 2012-03-08 | |
| EP12158679 | 2012-03-08 | ||
| EP12165054 | 2012-04-20 | ||
| PCT/EP2013/054800 WO2013132089A2 (en) | 2012-03-08 | 2013-03-08 | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01936A true IN2014MN01936A (enrdf_load_stackoverflow) | 2015-07-10 |
Family
ID=49117445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1936MUN2014 IN2014MN01936A (enrdf_load_stackoverflow) | 2012-03-08 | 2013-03-08 |
Country Status (7)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160324881A1 (en) | 2013-12-30 | 2016-11-10 | Oncoprevent Gmbh | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer |
| CN104237535B (zh) * | 2014-09-30 | 2016-02-10 | 天津市泌尿外科研究所 | 神经降压素在诊断去势抵抗性前列腺癌神经内分泌化亚型和判断预后中的应用 |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| US10900978B2 (en) * | 2015-02-27 | 2021-01-26 | Sphingotec Gmbh | Method for predicting the risk of obesity in a subject |
| KR102618553B1 (ko) * | 2022-08-31 | 2023-12-27 | 숙명여자대학교산학협력단 | 당뇨병 환자의 유방암 발병 예측 및 유방암 환자의 예후 예측용 바이오마커 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1427750B1 (en) | 2001-08-30 | 2010-12-08 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| PT1531791E (pt) | 2002-06-07 | 2010-12-16 | Dyax Corp | Prevenção e redução da isquémia |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20050233393A1 (en) * | 2004-02-27 | 2005-10-20 | Wynne-Edwards Katherine E | Dynamic hormone index as a biomarker for disease |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| DE102005003687A1 (de) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| ES2544954T3 (es) * | 2006-02-14 | 2015-09-07 | Universita' Degli Studi Di Siena | Péptidos multiméricos ramificados para diagnóstico y terapia de tumores |
| US8449864B2 (en) * | 2006-10-20 | 2013-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Neurotensin as a marker and therapeutic target for sepsis |
| WO2009044561A1 (ja) * | 2007-10-03 | 2009-04-09 | Shizuoka Prefecture | 抗ｐｒｏＮＴ／ＮＭＮモノクローナル抗体 |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質 |
| US8586043B2 (en) | 2009-01-07 | 2013-11-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1 |
| RU2550272C2 (ru) | 2009-08-27 | 2015-05-10 | Коваген Аг | Новые il-17-связывающие соединения и их медицинское применение |
| ES2441803T3 (es) | 2009-12-14 | 2014-02-06 | Scil Proteins Gmbh | Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| CN103308670B (zh) * | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| ES2676737T3 (es) * | 2012-10-02 | 2018-07-24 | Sphingotec Gmbh | Método para predecir el riesgo de contraer cáncer o para diagnosticar cáncer en un sujeto femenino |
-
2012
- 2012-10-08 CN CN201210585701.7A patent/CN103308689B/zh active Active
-
2013
- 2013-03-08 US US14/383,428 patent/US20150031144A1/en not_active Abandoned
- 2013-03-08 RU RU2014140432A patent/RU2642623C2/ru active
- 2013-03-08 JP JP2014560404A patent/JP6290795B2/ja active Active
- 2013-03-08 EP EP13710342.0A patent/EP2823313B1/en active Active
- 2013-03-08 IN IN1936MUN2014 patent/IN2014MN01936A/en unknown
- 2013-03-08 WO PCT/EP2013/054800 patent/WO2013132089A2/en active Application Filing
-
2020
- 2020-12-22 US US17/131,008 patent/US20210109102A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013132089A2 (en) | 2013-09-12 |
| WO2013132089A3 (en) | 2014-02-20 |
| JP6290795B2 (ja) | 2018-03-07 |
| CN103308689A (zh) | 2013-09-18 |
| RU2014140432A (ru) | 2016-04-27 |
| JP2015512047A (ja) | 2015-04-23 |
| CN103308689B (zh) | 2017-04-12 |
| RU2642623C2 (ru) | 2018-01-25 |
| WO2013132089A4 (en) | 2014-04-10 |
| US20210109102A1 (en) | 2021-04-15 |
| EP2823313A2 (en) | 2015-01-14 |
| US20150031144A1 (en) | 2015-01-29 |
| EP2823313B1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270864A (en) | Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders | |
| IN2013CN01129A (enrdf_load_stackoverflow) | ||
| MX356986B (es) | Metodo para detectar aductos de nucleosomas. | |
| MX349561B (es) | Método para detectar nucleosomas que contienen variantes de histonas. | |
| WO2010102195A3 (en) | Annexin a11 and associated genes as biomarkers for cancer | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX388168B (es) | Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer. | |
| WO2014028884A3 (en) | Cancer diagnostics using biomarkers | |
| MX382266B (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama. | |
| EP3586129C0 (en) | METHOD FOR ACCURATE DIAGNOSIS OF BIOMARKERS TARGETED AGAINST DISEASES IN LIQUID BIOPSY | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| IN2014MN01936A (enrdf_load_stackoverflow) | ||
| SG10201808585TA (en) | Compositions and methods related to diagnosis of prostate cancer | |
| SMT201900474T1 (it) | Microrna biomarcatori per identificare il rischio di e/o per diagnosticare tumore ai polmoni | |
| HK1220253A1 (zh) | 診斷前列腺癌症的方法 | |
| IN2014MN01940A (enrdf_load_stackoverflow) | ||
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| WO2012125805A3 (en) | Protein biomarkers for the diagnosis of prostate cancer | |
| IN2015DN01646A (enrdf_load_stackoverflow) | ||
| FR2996192B1 (fr) | Procede de determination de l'etat d'usure d'une piece et d'information d'un client | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| MX2018000189A (es) | Metodo para el diagnostico de la enfermedad de farber. | |
| WO2012040226A3 (en) | Gene expression in n-cadherin overexpressing prostate cancers and their controls |